Orange Book product · Brand (NDA)
RELPAX
ELETRIPTAN HYDROBROMIDE
At a glance
Dec 26, 2002
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 26, 2002
23 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
ELETRIPTAN HYDROBROMIDE
Strength
EQ 20MG BASE
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
NDA 021016
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 219143 · ANNORA PHARMA
- 2022ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 215467 · REGCON HOLDINGS
- 2020ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 209680 · CARLSBAD
- 2019ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 210708 · AUROBINDO PHARMA
- 2018ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 206787 · STEVENS J
- 2017ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 205186 · CHARTWELL RX
- 2017ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 205152 · MYLAN
- 2017ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 202040 · TEVA PHARMS USA
- 2017ELETRIPTAN HYDROBROMIDEGeneric (ANDA)
ANDA 206409 · ZYDUS PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
